Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus XIFYRM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus XIFYRM.
COR-OTICIN vs XIFYRM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
1-2 drops in each affected ear twice daily for 7 days.
500 mg orally twice daily with food.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: 70% unchanged; Fecal: 20%; Biliary: <10%
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic